m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01841)
Name
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide
Synonyms
CHEMBL574589; 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide
    Click to Show/Hide
Status
Investigative
Structure
Formula
C19H15NO4S
InChI
1S/C19H15NO4S/c21-19(20-22)17-8-4-5-9-18(17)25(23,24)16-12-10-15(11-13-16)14-6-2-1-3-7-14/h1-13,22H,(H,20,21)
InChIKey
WQRJSSRVHCJAKB-UHFFFAOYSA-N
PubChem CID
44478925
TTD Drug ID
D05THD
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Matrix metalloproteinase-12 (MMP-12)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide through regulating the expression of Matrix metalloproteinase-12 (MMP-12). [1], [2]
Matrix metalloproteinase-13 (MMP-13)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide through regulating the expression of Matrix metalloproteinase-13 (MMP-13). [2], [3]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide through regulating the expression of Matrix metalloproteinase-13 (MMP-13). [2], [4]
Matrix metalloproteinase-2 (MMP-2)
E3 ubiquitin-protein ligase Hakai (CBLL1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [2], [5]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [2], [6]
Matrix metalloproteinase-9 (MMP-9)
E3 ubiquitin-protein ligase Hakai (CBLL1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [2], [5]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [2]
References
Ref 1 The aberrant cross-talk of epithelium-macrophages via METTL3-regulated extracellular vesicle miR-93 in smoking-induced emphysema. Cell Biol Toxicol. 2022 Feb;38(1):167-183. doi: 10.1007/s10565-021-09585-1. Epub 2021 Mar 4.
Ref 2 Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors. J Med Chem. 2009 Oct 22;52(20):6347-61. doi: 10.1021/jm900335a.
Ref 3 FTO promotes cell proliferation and migration in esophageal squamous cell carcinoma through up-regulation of MMP13. Exp Cell Res. 2020 Apr 1;389(1):111894. doi: 10.1016/j.yexcr.2020.111894. Epub 2020 Feb 6.
Ref 4 METTL3 promotes experimental osteoarthritis development by regulating inflammatory response and apoptosis in chondrocyte. Biochem Biophys Res Commun. 2019 Aug 13;516(1):22-27. doi: 10.1016/j.bbrc.2019.05.168. Epub 2019 Jun 8.
Ref 5 CBLL1 is highly expressed in non-small cell lung cancer and promotes cell proliferation and invasion. Thorac Cancer. 2019 Jun;10(6):1479-1488. doi: 10.1111/1759-7714.13097. Epub 2019 May 23.
Ref 6 RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2. Melanoma Res. 2019 Aug;29(4):382-389. doi: 10.1097/CMR.0000000000000580.